The case for & against
Bull & Bear analysis
Arcturus Therapeutics, Inc. (NASDAQ: ARCT) is a biopharmaceutical company specializing in mRNA-based therapeutics and vaccines, focusing primarily on addressing unmet medical needs in the areas of cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. The company is leveraging its proprietary lunar lipid-mediated delivery platform to develop innovative therapies that promise improvements in treatment efficacy and safety. Arcturus is currently progressing through pivotal clinical trials for its leading candidates, including ARCT-032 for CF and ARCT-810 for OTC deficiency, positioning itself as a serious contender in the biotechnology field with a focus on rare diseases.
Bull says
- ↑ARCT-032 CF program entering Phase II 12-week study in H1 2026
- ↑Cash balance of $213.4M funds operations through 2028
- ↑CSL partnership on CoStave yields first US revenue milestone
- ↑Proactive FDA engagement on ARCT-810 regulatory pathway reduces approval risk
- ↑Rare disease focus addresses unmet needs in CF and OTC deficiency
- ↑Positive book-to-price and liquidity scores indicate relative value opportunity
Bear says
- ↓Q1 2026 net loss of $0.95/sh and zero quarterly revenue
- ↓YoY revenue down $27.3M reflects pre‐commercial stage decline
- ↓Negative earnings yield and profitability scores highlight operational losses
- ↓Revenue drop from reduced CSL collaboration underscores partnership reliance
- ↓Negative momentum and size factor scores suggest weak market sentiment
- ↓Deeply negative growth score indicates challenges scaling revenue
Investment themes with ARCT
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- we're expressing confidence on today's call that later this year we should have sufficient enrollment and data to inform our next steps. So I think we're going to be in a really good place to understand where we are with this program later this year.
- Our expectation and hope is that the pediatric opportunity and unmet medical need is the greatest, and the one that we feel we need to be spending our greatest attention to once we're given the opportunity to do so.
- at the completion of our Cohort 3 study, which went up from 5 to 10 to 15 milligrams daily for 28 days, that we were given the ability to move forward with a longer study, allowing for either 10 or 15 milligrams daily in cohort four.
Bear points
- forward-looking statements
- Year over year quarterly revenue decreased by $27.3 million. The decline was driven by reductions in revenue from our CSL collaboration as Arcturus refocuses on our rare disease clinical programs.